Myomo CMO sells 15,488 shares at $1.27

Available on EDGAR 09/14/2026 - 04:34 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:30 PM EDT Learn about SEC filing dates

The filer has since corrected this document, so the figures below are the ones originally reported and some of them may have changed. Read the amended Form 4/A for what the company says now.

Rhea-AI Filing Summary

MYOMO, INC. (MYO) reported that Chief Medical Officer Harry Kovelman sold 15,488 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted-average price of $1.2709 per share, with individual trade prices ranging from $1.25 to $1.29 per share.

After this sale, he directly holds 90,245 shares of MYOMO common stock. No transactions in this filing are reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 15,488 shares

Net Sell 1 txn

Insider Kovelman Harry

Role Chief Medical Officer

Sold 15,488 shs ($20K)

Share of Position Sold 14.6%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	15,488	$1.2709	$20K

Holdings After Transaction: Common Stock — 90,245 shares (Direct)

Holdings Before and After: Common Stock, 105,733 to 90,245 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. Represents average sales price. Transactions were completed in multiple lots at prices ranging from $1.25 to $1.29 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Key Figures

Shares sold: 15,488 shares Weighted-average sale price: $1.2709 per share Sale price range: $1.25–$1.29 per share +2 more

5 metrics

Shares sold 15,488 shares Common stock sale by Chief Medical Officer on September 11, 2026

Weighted-average sale price $1.2709 per share Average price for the 15,488 shares sold on September 11, 2026

Sale price range $1.25–$1.29 per share Range of individual trade prices for the reported sale

Shares held after transaction 90,245 shares Direct holdings of Harry Kovelman after the reported sale

Net buy/sell shares 15,488 shares net sold Net effect of transactions reported in this Form 4

Key Terms

weighted-average price, open market or private transaction, Rule 10b5-1

3 terms

weighted-average price financial

"Represents average sales price. Transactions were completed in multiple lots"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 regulatory

"No transactions in this filing are reported as made under a Rule 10b5-1 trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYO report for Chief Medical Officer Harry Kovelman?

MYOMO reported that Chief Medical Officer Harry Kovelman sold 15,488 shares of common stock on September 11, 2026 at a weighted-average price of $1.2709 per share, with trades executed between $1.25 and $1.29 per share.

How many MYO shares does Harry Kovelman hold after the reported sale?

Following the September 11, 2026 transaction, Harry Kovelman directly holds 90,245 shares of MYOMO common stock, as reported in the Form 4.

Was the MYO insider sale by Harry Kovelman under a Rule 10b5-1 trading plan?

The filing indicates that no Rule 10b5-1 plan is affirmed for this transaction, and the footnote only describes the average sales price and trade price range, without referencing any trading plan.

What price range were the MYO shares sold at in this Form 4?

The 15,488 MYO shares were sold at prices ranging from $1.25 to $1.29 per share, with a reported weighted-average sales price of $1.2709 per share.

Is this MYO Form 4 transaction a purchase or a sale of shares?

This Form 4 reports a sale of MYOMO common stock by Chief Medical Officer Harry Kovelman, totaling 15,488 shares on September 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovelman Harry

(Last) (First) (Middle)

C/O MYOMO, INC.

45 BLUE SKY DR., SUITE 101

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		15,488	D	$1.2709(1)	90,245	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents average sales price. Transactions were completed in multiple lots at prices ranging from $1.25 to $1.29 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

	/s/ Amy B Vetrano-Palmer, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)